Testing effectiveness (Phase 2)Not Yet RecruitingNCT07263360
What this trial is testing
Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
Who this might be right for
BTC
Tianjin Medical University Cancer Institute and Hospital 29